MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A
Phase 3 Study of Guselkumab in Plaque Psoriasis
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Guselkumab Met Co-Primary Endpoints in Patients with Moderate to Severe Plaque
Psoriasis
* Janssen today presented results from a phase 3 study of guselkumab in 837
patients with moderate to severe plaque psoriasis ("VOYAGE 1" study).
* Janssen stated in a press release issued today that "new phase 3 data show
significant efficacy versus placebo and superiority of guselkumab versus
Humira® in treatment of moderate to severe plaque psoriasis" and that
guselkumab "demonstrates significant efficacy compared with tumor necrosis
factor blocker Humira® across all major study endpoints through 48 weeks of
treatment".
* According to Janssen, the two co-primary endpoints of the study were met:
Primary endpoints included improving signs and symptoms of psoriasis, while
delivering clear or almost clear skin (IGA 0 or 1 and PASI 90) at week 16,
in patients receiving guselkumab compared to placebo. In addition, according
to Janssen, all major secondary endpoints achieved statistical significance
in comparisons of guselkumab versus Humira®.
* Guselkumab is a fully human antibody intended to target IL-23 identified
from MorphoSys's HuCAL antibody library.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced
today that its licensee Janssen Research & Development, LLC (Janssen) has
reported positive results from a clinical phase 3 study with 837 patients
examining guselkumab, a fully human antibody intended to target IL-23 identified
from MorphoSys's HuCAL antibody library, in patients with moderate to severe
plaque psoriasis.
Janssen presented the data from its "VOYAGE 1" study today in a late breaking
session at the 25th congress of the European Academy of Dermatology and
Venereology (EADV) in Vienna, Austria. The randomized, double-blind, placebo-
and active-comparator-controlled study evaluated guselkumab, in comparison to
placebo and the active comparator adalimumab (Humira®), in the treatment of
moderate to severe plaque psoriasis.
"We are excited about the positive results released by our licensee Janssen with
respect to guselkumab in the treatment of moderate to severe plaque psoriasis",
said Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "We are proud
of our long-standing collaboration with Janssen and we are looking forward to
the further updates about the development of guselkumab going forward."
Further detailed information about the clinical study results can be found in a
press release issued today by Janssen.
About Psoriasis
Psoriasis is an autoimmune disease which is characterized by patches of abnormal
skin. These skin patches are typically red, itchy, and scaly. They may vary in
severity from small and localized to complete body coverage. There are five main
types of psoriasis: plaque, guttate, inverse, pustular, and erythrodermic.
Plaque psoriasis, also known as psoriasis vulgaris, makes up about 90% of cases.
It typically presents with red patches with white scales on top. Psoriasis is
usually chronic and has a high morbidity and negative impact on patients'
quality of life. In 2015 prevalence of the disease was 16 million patients in
the seven major countries (USA, Japan, France, Germany, Italy, Spain, and Great
Britain), as estimated by independent market intelligence experts.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
Humira® is a registered trademarks of AbbVie Inc.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/2046046/764507.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.10.2016 - 11:44 Uhr
Sprache: Deutsch
News-ID 498201
Anzahl Zeichen: 6647
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 858 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
